Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Other financing activities (2020 - 2024)

Historic Other financing activities for Beauty Health (SKIN) over the last 4 years, with Q4 2024 value amounting to -$302000.0.

  • Beauty Health's Other financing activities rose 1516.85% to -$302000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$884000.0, marking a year-over-year decrease of 5189.0%. This contributed to the annual value of -$302000.0 for FY2024, which is N/A changed from last year.
  • Per Beauty Health's latest filing, its Other financing activities stood at -$302000.0 for Q4 2024, which was up 1516.85% from -$356000.0 recorded in Q4 2023.
  • Beauty Health's 5-year Other financing activities high stood at $21.3 million for Q3 2021, and its period low was -$356000.0 during Q4 2023.
  • In the last 4 years, Beauty Health's Other financing activities had a median value of $3686.5 in 2020 and averaged $3.5 million.
  • Per our database at Business Quant, Beauty Health's Other financing activities soared by 904458.83% in 2021 and then soared by 1516.85% in 2024.
  • Quarter analysis of 4 years shows Beauty Health's Other financing activities stood at $465909.0 in 2020, then skyrocketed by 4480.51% to $21.3 million in 2021, then tumbled by 101.67% to -$356000.0 in 2023, then rose by 15.17% to -$302000.0 in 2024.
  • Its last three reported values are -$302000.0 in Q4 2024, -$356000.0 for Q4 2023, and -$226000.0 during Q3 2023.